Meliglix (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin release and suppress glucagon when blood glucose is elevated, thereby lowering overall glucose concentrations.

The dose of sitagliptin is individualized by the prescribing healthcare professional based on the patient’s renal function, glycemic targets, and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule for each patient.

Safety data for sitagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Meliglix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Sitagliptin belongs to the DPP‑4 inhibitor class, which generally offers a lower risk of hypoglycemia compared with sulfonylureas and does not cause weight gain. Compared with GLP‑1 receptor agonists, it is oral rather than injectable but provides a modest reduction in HbA1c.

Meliglix tablets should be stored at room temperature, below 25 °C, in their original packaging. Protect them from excess moisture, direct sunlight and heat to maintain potency throughout the shelf life.

Meliglix is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed by a healthcare professional.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, and acute kidney injury, particularly in patients with pre‑existing renal impairment. Prompt medical attention is required if these symptoms appear.

Meliglix is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, a history of pancreatitis, or those taking medications that may significantly increase sitagliptin exposure.